Severe hypertriglyceridemia and pancreatitis: presentation and management
The DOI matches its Crossref record; 83 of the 84 references it cites were found in a registry or an index.
Abstract
Purpose of review Hypertriglyceridemia (HTG) is a well recognized cause of acute pancreatitis accounting for approximately up to 10% of all cases and even up to 50% of all cases in pregnancy. Both primary and secondary disorders of lipoprotein metabolism may be associated with hypertriglyceridemic pancreatitis (HTGP). The purpose of this review is to provide an overview of the current studies on presentation and management of HTGP. Recent findings/conclusion Hydrolysis of triglycerides by pancreatic lipase and formation of free fatty acids that induce inflammatory changes are postulated to account for the development of HTGP, yet the exact pathophysiology remains unclear. The clinical features of patients with HTGP are generally not different from patients with acute pancreatitis of other causes, and there is some evidence that HTGP is associated with a higher severity or a higher complication rate. There is no clear evidence as to which HTG patients will develop pancreatitis. Several studies have evaluated the effect of apheresis, the benefit of insulin and/or heparin treatment and the use of different antihyperlipidemic agents in HTGP. Dietary modifications resemble the key features in the long-term management of HTG. Whether HTG may cause chronic pancreatitis in the long-term follow-up remains controversial.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Such an approach has been recommended by the National Lipid Association 10 and International Atherosclerosis Society 117 for patients with HTG or VHTG.”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [10]
In the citing paper
“In the acute setting apheresis is able to lower TG levels rapidly.123”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [123]
In the citing paper
“In the acute setting, plasmapheresis is able to rapidly lower TG levels. 308”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [308]
In the citing paper
“Overall, alcohol abuse and gallstone disease account for at least 80% of all cases of acute pancreatitis, with hypertriglyceridemia contributing Ϸ10% of cases.105,134”
From Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association (2011) · cites this paper as [105]
In the citing paper
“Because documentation for a specific threshold in triglyceride-induced pancreatitis is lacking, levels associated with increased risk are arbitrarily defined as triglyceride levels Ն1000 mg/dL”
From Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association (2011) · cites this paper as [105]
Citations
Cites
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect
Tunaru, S., Kero, J., Schaub, A., Wufka, C., Blaukat, A., Pfeffer, K., & Offermanns, S. (2003) · Nature Medicine · doi:10.1038/nm824 · Cited by 791
Molecular Identification of High and Low Affinity Receptors for Nicotinic Acid
Wise, A., Foord, S. M., Fraser, N. J., Barnes, A. A., Elshourbagy, N., Eilert, M., Ignar, D. M., Murdock, P. R., Steplewski, K., Green, A., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210695200 · Cited by 539
Issues in Hyperlipidemic Pancreatitis
Yadav, D., & Pitchumoni, C. S. (2003) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200301000-00016 · Cited by 435
(1995) · PubMed · Cited by 423
Safety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408
Hypertriglyceridemic Pancreatitis: Presentation and Management
Tsuang, W., Navaneethan, U., Ruiz, L., Palascak, J. B., & Gelrud, A. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.27 · Cited by 395
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
Jones, P. H., & Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.08.076 · Cited by 387
Research works printed but not linked: 1
- Speck, 1865, A case of lipidemia., Arch Verin Wissenschaftl Heilkunde, 1, 232
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“In the acute setting, plasmapheresis is able to rapidly lower TG levels.(384) Volanesorsen has been recently approved by the EMA as an adjunct to diet in adult patients with genetically confirmed FCS who are at high-risk for pancreatitis.”
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
“In the acute setting, plasmapheresis is able to rapidly lower TG levels.(308)”
BackgroundNordestgaard, B. G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306249 · Cited by 1,116
“be a miniature of what happens in the pancreas at extremely high plasma triglycerides, with liberation of toxic amounts of free fatty acids, severe inflammation including lipid-filled macrophages, necrosis, and pancreatitis.(109,110) Also, triglyceride-rich lipoproteins, unlike LDL particles, can be taken up directly…”
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 773
“Management of patients with hypertriglyceridemia For patients with very high triglycerides ($500 mg/dL), the primary objective of therapy is to lower the triglyceride level to ,500 mg/dL to reduce the risk of pancreatitis.(197,201) For patients with hypertriglyceridemia who have high triglycerides (200–499 mg/dL), the…”
BackgroundESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Skulas-Ray, A. C., Wilson, P. W. F., Harris, W. S., Brinton, E. A., Kris-Etherton, P. M., Richter, C. K., Jacobson, T. A., Engler, M. B., Miller, M., Robinson, J. G., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000709 · Cited by 512
Current knowledge of hypertriglyceridemic pancreatitis
Valdivielso, P., Ramírez-Bueno, A., & Ewald, N. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.08.008 · Cited by 439
“However, there are some frequently cited reviews proposing valuable treatment algorithms for HTG-AP [92,93].”
BackgroundSelf-citationVirani, S. S., Morris, P. B., Agarwala, A., Ballantyne, C. M., Birtcher, K. K., Kris-Etherton, P. M., Ladden-Stirling, A. B., Miller, M., Orringer, C. E., & Stone, N. J. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.011 · Cited by 341
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.016 · Cited by 304
Nawaz, H., Koutroumpakis, E., Easler, J., Slivka, A., Whitcomb, D. C., Singh, V. P., Yadav, D., & Papachristou, G. I. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.261 · Cited by 296
Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis
Pedersen, S. B., Langsted, A., & Nordestgaard, B. G. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.6875 · Cited by 270
Hypertriglyceridemic pancreatitis: Epidemiology, pathophysiology and clinical management
de Pretis, N., Amodio, A., & Frulloni, L. (2018) · United European Gastroenterology Journal · doi:10.1177/2050640618755002 · Cited by 265
“The most common causes of AP are gallstones, alcoholism and HTG.(1,2) Although the risk of AP in patients with elevated serum triglycerides has not been clearly defined, high chylomicron levels are known to be necessary to trigger AP.”
BackgroundInfluentialWhat Have We Learned About Acute Pancreatitis in Children?
Bai, H. X., Lowe, M. E., & Husain, S. Z. (2011) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e3182061d75 · Cited by 254
“Co fluids, lipid-lowering agents, or apheresis (57,58).”
Systematic review of hypertriglyceridemia-induced acute pancreatitis: A more virulent etiology?
Carr, R. A., Rejowski, B. J., Cote, G. A., Pitt, H. A., & Zyromski, N. J. (2016) · Pancreatology · doi:10.1016/j.pan.2016.02.011 · Cited by 247
“In contrast, both medical (insulin and/or heparin infusion, oral antihyperlipidemic medications) and interventional (plasmapheresis or hemodiafiltration combined with resin-mediated absorption [41]) treatments rapidly lower circulating TG concentration, with plasmapheresis resulting in the most rapid reduction of seru…”
BackgroundCarr, S. S., Hooper, A. J., Sullivan, D. R., & Burnett, J. R. (2019) · Pathology · doi:10.1016/j.pathol.2018.11.006 · Cited by 193
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.012 · Cited by 192
“In the acute setting apheresis is able to lower TG levels rapidly.(123)”
BackgroundDavidson, M. H., Johnson, J., Rooney, M. W., Kyle, M. L., & Kling, D. F. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.01.002 · Cited by 191
Lipid-Modifying Therapies and Risk of Pancreatitis: A Meta-analysis
Preiss, D., Tikkanen, M. J., Welsh, P., Ford, I., Lovato, L. C., Elam, M. B., LaRosa, J. C., DeMicco, D. A., Colhoun, H. M., Goldenberg, I., et al. (2012) · JAMA · doi:10.1001/jama.2012.8439 · Cited by 181
“creatitis andthat loweringof triglyceride levels should be clinically beneficial.(7)”
BackgroundPoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021
Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Archives of Medical Science · doi:10.5114/aoms/141941 · Cited by 186
Gene therapy for lipoprotein lipase deficiency
Gaudet, D., Méthot, J., & Kastelein, J. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283555a7e · Cited by 178
Acute pancreatitis during pregnancy: a review
Ducarme, G., Maire, F., Chatel, P., Luton, D., & Hammel, P. (2014) · Journal of Perinatology · doi:10.1038/jp.2013.161 · Cited by 167
Familial chylomicronemia syndrome: an under‐recognized cause of severe hypertriglyceridaemia
Baass, A., Paquette, M., Bernard, S., & Hegele, R. A. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13016 · Cited by 144
Acute Pancreatitis: Updates for Emergency Clinicians
Waller, A., Long, B., Koyfman, A., & Gottlieb, M. A. (2018) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2018.08.009 · Cited by 142
Genetic bases of hypertriglyceridemic phenotypes
Johansen, C. T., & Hegele, R. A. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283471972 · Cited by 127
2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)
Committee for the Korean Guidelines for the Management of Dyslipidemia (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.46.3.275 · Cited by 132
Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122
Diagnosis and treatment of apolipoprotein B dyslipoproteinemias
Sniderman, A. D., Couture, P., & Graaf, J. D. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.50 · Cited by 133
“The genetic causes of marked hyperchylomicronemia include failure to synthesize active LPL or apoC-II, a cofactor essential for LPL activity”
BackgroundGubenšek, J., Buturović‐Ponikvar, J., Romozi, K., & Ponikvar, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102748 · Cited by 116
“To further reduce triglyceride levels fibrates, nicotinic acid and omega-3 fatty acids can be used and regular plasma exchange treatment has also been described in the prevention of recurrent attacks [21].”
BackgroundTreatment options for severe hypertriglyceridemia (SHTG): the role of apheresis
Ewald, N., & Kloer, H.-U. (2012) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-012-0042-x · Cited by 112
“Several mechanisms for the disease have been proposed, including the hydrolysis of TGs forming free fatty acids inducing inflammation, chylomicrons inducing hyperviscosity leading to ischemia, and, finally, genetic predisposition [13, 14].”
BackgroundSelf-citationFibrosis Reduces Severity of Acute-on-Chronic Pancreatitis in Humans
Acharya, C., Cline, R. A., Jaligama, D., Noel, P., DeLany, J. P., Bae, K. T., Furlan, A., Baty, C. J., Karlsson, J. M., Rosario, B. L., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.012 · Cited by 111
“AP andCP share some common etiologies such as alcohol consumption,(19) genetic mutations (eg, CFTR, PRSS1), obstructive lesions (eg, a mass), and metabolic causes (eg, hyperlipidemia).(26,27) Recent studies suggest AP, recurrent AP, and CP are part of a continuum.”
Complications Following Antidotal Use of Intravenous Lipid Emulsion Therapy
Levine, M., Skolnik, A. B., Ruha, A., Bosak, A. R., Menke, N. B., & Pizon, A. F. (2013) · Journal of Medical Toxicology · doi:10.1007/s13181-013-0356-1 · Cited by 120
“It is well known that hypertriglyceridemia can induce pancreatitis [16–18].”
BackgroundHan, P., Wei, G., Cai, K., Xiang, X., Deng, W. P., Li, Y. B., Kuang, S., Dong, Z., Zheng, T., Luo, Y., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14768 · Cited by 104
Comprehensive review on the pathogenesis of hypertriglyceridaemia-associated acute pancreatitis
Qiu, M., Zhou, X., Zippi, M., Goyal, H., Basharat, Z., Jagielski, M., & Hong, W. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2265939 · Cited by 101
“Plasma hyperviscosity is also involved in the pathogenesis of HTAP [24,25,27,80].”
BackgroundSevere Hypertriglyceridemia Influenced by Alcohol (SHIBA)
Bessembinders, K., Wielders, J., & van de Wiel, A. (2011) · Alcohol and Alcoholism · doi:10.1093/alcalc/agq088 · Cited by 95
“Although HT is often asymptomatic, it is almost certainly a risk factor for cardiovascular disease (Yuan et al., 2007), and patients with severe HT are generally considered to be at increased risk for acute pancreatitis (Ewald et al., 2009).”
BackgroundLin, X.-Y., Zeng, Y., Zhang, Z., Lin, Z.-H., Chen, L., & Ye, Z. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i29.3946 · Cited by 94
HIIT is not superior to MICT in altering blood lipids: a systematic review and meta-analysis
Wood, G., Murrell, A., van der Touw, T., & Smart, N. (2019) · BMJ Open Sport & Exercise Medicine · doi:10.1136/bmjsem-2019-000647 · Cited by 85
Huang, C., Liu, J., Lu, Y., Fan, J., Wang, X., Liu, J., Zhang, W., & Zeng, Y. (2016) · Journal of Clinical Apheresis · doi:10.1002/jca.21453 · Cited by 79
“The incidence of hypertriglyceridemia-induced acute pancreatitis (HTGP) increased rapidly to 56% according to recent reports [3].”
BackgroundAcute pancreatitis in pregnancy
Sun, L., Li, W., Geng, Y., SHEN, B., & Li, J. (2011) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/j.1600-0412.2011.01072.x · Cited by 78
“considered that pregnancy was one of the secondary causes of hypertriglyceridemia, and hypertriglyceridemia accounted for up to 50% of all pancreatitis cases in pregnancy (15).”
BackgroundAapro, M., André, F., Blackwell, K., Calvo, E., Jahanzeb, M., Papazisis, K. T., Porta, C., Pritchard, K. I., & Ravaud, A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu021 · Cited by 79
“High triglyceride levels (≥500 mg/dl) should be lowered promptly with fibrates because of the risk of acute pancreatitis [20, 23, 37, 42].”
BackgroundYang, X., Chen, J., Wang, J., Ma, S., Feng, W., Wu, Z., Guo, Y., Zhou, H., Mi, W., Chen, W., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.06.001 · Cited by 87
Severe Hypertriglyceridemia: An indication for apheresis?
Ewald, N., & Kloer, H.-U. (2009) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(09)71810-0 · Cited by 71
Self-citationCurrent and future trends in the lipid lowering therapy
Okopień, B., Bułdak, Ł., & Bołdys, A. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.03.016 · Cited by 72
“Nevertheless without any doubt highly elevated TG are the cause of potentially fatal acute pancreatitis [6].”
BackgroundApoc2 loss-of-function zebrafish mutant as a genetic model of hyperlipidemia
Liu, C., Gates, K. P., Fang, L., Amar, M. J., Schneider, D. A., Geng, H., Huang, W. G., Kim, J., Pattison, J., Zhang, J., et al. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.019836 · Cited by 71
“…and chylomicronemia, and often manifest eruptive xanthomas, lipemia retinalis and acute and recurrent pancreatitis, which can be lethal (Breckenridge et al., 1978; Cox et al., 1978; Ewald et al., 2009; Goldberg and Merkel, 2001; Miller et al., 2011; Scherer et al., 2014; Watts et al., 2013).”
BackgroundPothoulakis, I., Paragomi, P., Archibugi, L., Tuft, M., Talukdar, R., Kochhar, R. K., Goenka, M. K., Gulla, A., Singh, V. K., González, J. A., et al. (2020) · Pancreatology · doi:10.1016/j.pan.2020.02.010 · Cited by 72
2015 Korean Guidelines for Management of Dyslipidemia
Committee for Guidelines for Management of Dyslipidemia (2015) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2015.4.1.61 · Cited by 71
Guía de la ESC/EAS sobre el manejo de las dislipemias
Reiner, Ž., Catapano, A. L., Backer, G. D., Graham, I. M., Taskinen, M., Wiklund, O., Agewall, S., Alegría, E., Chapman, M. J., Durrington, P. N., et al. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.09.014 · Cited by 80
Clinical Study of 224 Patients with Hypertriglyceridemia Pancreatitis
Zhang, X., Li, F., Zhen, Y.-M., Li, A., & Fang, Y. (2015) · Chinese Medical Journal · doi:10.4103/0366-6999.161361 · Cited by 63
“The treatment plan must be tailored to each patient.[6,31] Diet, lifestyle changes and control of secondary factors are key to the treatment, and lipid‐lowering drugs Table 5: Characteristics of the HGTP compared with biliary AP”
BackgroundBenefits and risks of the treatment with fibrates––a comprehensive summary
Okopień, B., Bułdak, Ł., & Bołdys, A. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1537780 · Cited by 61
“Hypertriglyceridemia is considered as the third cause of acute pancreatitis [50] and follows cholelithiasis and alcohol abuse.”
BackgroundXenoulis, P. G., Levinski, M. D., Suchodolski, J. S., & Steiner, J. M. (2010) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2010.0644.x · Cited by 56
“Regardless of the possible explanation, these findings suggest that serum triglyceride concentrations during the course of pancreatitis may not accurately reflect the true triglyceride concentrations.(16,17,19) Therefore, it might be recommended that serum triglyceride concentrations be measured after resolution of pa…”
BackgroundKastelein, J. J. P., Ross, C. J. D., & Hayden, M. R. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.063 · Cited by 56
“Pregnancy is an important trigger of pancreatitis and can be life-threatening in LPL deficiency (Ma et al. , 1993; Ewald et al. , 2009); however, for this treated patient the pregnancy went very well and she delivered a healthy baby.”
Karalis, D. G. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0462-y · Cited by 59
“In addition, mild to moderate hypertriglyceridemia may occur in pancreatitis due to other causes [29].”
BackgroundBashir, B., Ho, J. H., Downie, P., Hamilton, P., Ferns, G. A., Datta, D. B. N., Cegla, J., Wierzbicki, A. S., Dawson, C., Jenkinson, F., et al. (2023) · Metabolites · doi:10.3390/metabo13050621 · Cited by 52
“However, when the pancreatic microcirculation is sluggish in chylomicronaemia, there is time for it to release fatty acids and lysolipids, which are cytotoxic [22,58,59].”
Background2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I. M., Backer, G. D., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0157 · Cited by 62
Thompson, G. R. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833e13fd · Cited by 49
Current Diagnosis and Management of Primary Chylomicronemia
Okazaki, H., Gotoda, T., Ogura, M., Ishibashi, S., Inagaki, K., Daida, H., Hayashi, T., Hori, M., Masuda, D., Matsuki, K., et al. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17054 · Cited by 48
Wu, B. U., Batech, M., Dong, E. Y., Duan, L., Yadav, D. K., & Chen, W. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5226-x · Cited by 46
Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy
Wiklund, O., Pirazzi, C., & Romeo, S. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0397-8 · Cited by 45
“Patients with very high TG (>10 mmol/L or >900 mg/dL) should immediately start therapy because of the risk of pancreatitis [15].”
BackgroundAcute pancreatitis associated with severe hypertriglyceridaemia; A retrospective cohort study
Charlesworth, A., Steger, A. C., & Crook, M. A. (2015) · International Journal of Surgery · doi:10.1016/j.ijsu.2015.08.080 · Cited by 47
“[11] proposed that pancreatic lipase hydrolyses triglycerides and the resultant free fatty acids provoke inflammatory changes and free radical damage potentiating acute pancreatitis.”
BackgroundDragoman, M., Curtis, K. M., & Gaffield, M. E. (2016) · Contraception · doi:10.1016/j.contraception.2015.08.002 · Cited by 43
“Though the exact pathophysiologic mechanisms of hypertriglyceridemic pancreatitis are unclear and the absolute risk of pancreatitis based on triglyceride levels has not been clearly defined, limited evidence supports the claim that serum triglyceride levels greater than 1000 mg/dl are necessary to induce pancreatitis…”
BackgroundPROMETHEUS: an observational, cross-sectional, retrospective study of hypertriglyceridemia in Russia
IuA, K., & Владиславовна, Х. Ю. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0268-2 · Cited by 46
“Acute pancreatitis represents the most clinically relevant complication of hypertriglyceridemia [1], with up to 10 % of all cases being due to elevated TGs [12].”
BackgroundInfluentialExtreme hypertriglyceridemia managed with insulin
Thuzar, M., Shenoy, V. V., Malabu, U. H., Schrale, R. G., & Sangla, K. S. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.09.004 · Cited by 42
Analysis of the clinical profile and treatment efficiency of hyperlipidemic acute pancreatitis
Zhou, W., Liu, Q., Wang, Z., Yao, L., Chen, J., & Yang, X. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02057-5 · Cited by 41
Thirty-eight cases of acute pancreatitis in pregnancy: A 6-year single center retrospective analysis
Zhang, D.-L., Huang, Y., Li, Y., Phu, A. L., Ran, X., & Li, S. (2013) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-013-1125-8 · Cited by 41
Eren, G. A., Altun, D., Çukurova, Z., Hergünsel, O., & Yaşar, L. (2012) · Journal of Anaesthesiology Clinical Pharmacology · doi:10.4103/0970-9185.94913 · Cited by 41
Tian, F., Li, H., & Yang, Z. (2019) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_550_18 · Cited by 39
“[39] The most common definition of hypertriglyceridemic AP reported in the literature is AP with a serum triglyceride level of 1000 mg/dL.[40] Studies have found that patients with hypertriglyceridemia >500 mg/dL have higher 24‐h APACHE‐II scores, which are in turn associated with increased systemic complications, hig…”
BackgroundOpel, D., Kramer, O. N., Chevalier, M., Bigby, M., & Albrecht, J. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15207 · Cited by 36
Harper, S., & Cheslyn-Curtis, S. (2010) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2010.010196 · Cited by 38
Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Diagnostyka Laboratoryjna · doi:10.5604/01.3001.0015.4805 · Cited by 36
Practical Management of Everolimus-Related Toxicities in Patients with Advanced Solid Tumors
Grünwald, V., Weikert, S., Pavel, M. E., Hörsch, D., Lüftner, D., Janni, W., Geberth, M., & Weber, M. M. (2013) · Oncology Research and Treatment · doi:10.1159/000350625 · Cited by 35
Hypertriglyceridemia Acute Pancreatitis: Animal Experiment Research
Wang, L., Xu, T., Wang, R., Wang, X., & Wu, D. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-06928-0 · Cited by 34
“The treatment of HTG-AP in humans has not reached a consensus, and there is no specific medicine for HTG-AP [146].”
BackgroundHypertriglyceridemia Induced Pancreatitis: plasmapheresis or conservative management?
Dichtwald, S., Meyer, A., Zohar, E., Ifrach, N., Rotlevi, G., & Fredman, B. (2021) · Journal of Intensive Care Medicine · doi:10.1177/08850666211054365 · Cited by 33
“Furthermore, it should be remembered that the drug induced increase in lipoprotein activity is temporary.(11,12) As a result, other methods of decreasing blood triglyceride levels have been sort.”
BackgroundThe Evolving Story of Multifactorial Chylomicronemia Syndrome
Paquette, M., & Bernard, S. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.886266 · Cited by 34
Hartl, W. H., Parhofer, K. G., Kuppinger, D., Rittler, P., & Arends, J. (2013) · Aktuelle Ernährungsmedizin · doi:10.1055/s-0033-1349536 · Cited by 34
Zhu, Y., Huang, Y., Sun, H., Chen, L., Yu, H., Shi, L., Xia, W., Sun, X., Yang, Y., & Huang, H. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02112-1 · Cited by 32
“Patients discharged from the hospital should receive long-term fibrate treatment to lower blood lipids and recommended lifestyle modifications to exercise more, control body weight, limit intake of fats and carbohydrates, and avoid alcohol consumption [28, 29].”
BackgroundSevere Acute Pancreatitis Due to Tamoxifen-Induced Hypertriglyceridemia with Positive Rechallenge
Sakhri, J., Salem, C. B., Harbi, H., Fathallah, N., & Ltaief, R. (2015) · PubMed · doi:10.6092/1590-8577/3626 · Cited by 32
“Moreover, the degradation of triglycerides to free fatty acids by pancreatic lipases may lead to further cytotoxic injuries which increase inflammatory mediators resulting in aggravation of the pancreatitis [5].”
BackgroundResidual lipid risk in atherosclerotic cardiovascular disease
Nordestgaard, B. G., & Hegele, R. A. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag087 · Cited by 31
Jeong, Y. K., & Kim, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112239 · Cited by 32
“, uncontrolled diabetes, alcoholism, medications, and pregnancy) may be associated with hypertriglyceridemic pancreatitis [35].”
BackgroundInfluentialHypertriglyceridemia-induced acute pancreatitis
Ewald, N. (2013) · Clinical Lipidology · doi:10.2217/clp.13.44 · Cited by 34
Self-citationSue, L. Y., Batech, M., Yadav, D. K., Pandol, S. J., Blumentals, W. A., von Krusenstiern, L. S., Chen, W., & Wu, B. U. (2017) · Pancreas · doi:10.1097/mpa.0000000000000860 · Cited by 31
Wang, Y., Attar, B. M., Hinami, K., Jaiswal, P., Yap, J. E., Jaiswal, R., Devani, K., Simons-Linares, C. R., & Demetria, M. V. (2017) · Pancreas · doi:10.1097/mpa.0000000000000937 · Cited by 31
Analyzing and identifying risk factors for acute pancreatitis with different etiologies in pregnancy
Jin, J., Yu, Y., Zhong, M., & Zhang, G. (2014) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2014.913132 · Cited by 30
“Dietary modifications resembled key features in the long-term management of hypertriglyceridemia [15].”
BackgroundImpact of Hypertriglyceridemia on the Outcome of Acute Biliary Pancreatitis
Zeng, Y., Lu, Y., Huang, C., Wang, X., & Zhang, W. (2014) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000333 · Cited by 30
“3 mmol/L (about 1000 mg/dL), AP could emerge spontaneously and aggravate with the rise of TG concentration.(6,7) In contrast, AP gradually tends to be stable and can be prevented when plasma TG level drops to 5.”
BackgroundLai, M., Fang, F., Ma, Y., Yang, J., Huang, J., Li, N., Kang, M., Xu, X., Zhang, J., Wang, Y., et al. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3950652 · Cited by 31
Toth, P. P., Grabner, M., Ramey, N., & Higuchi, K. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.09.029 · Cited by 30
“However, challenges remain in identifying individuals at high risk for development of severe HTG complications, especially acute pancreatitis [5].”
BackgroundChen, R., Hornemann, T., Štefanić, S., Schraner, E. M., Zuellig, R. A., Reding, T., Malagola, E., Henstridge, D. C., Hills, A. P., Graf, R., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05156-x · Cited by 29
Clinical significance of serum triglyceride elevation at early stage of acute biliary pancreatitis
Cheng, L., Luo, Z., Xiang, K., Ren, J., Huang, Z., Tang, L., & Tian, F. (2015) · BMC Gastroenterology · doi:10.1186/s12876-015-0254-x · Cited by 28
“It has been reported that more than 50% of non-HTGinduced AP patients demonstrate mild-to-moderate TG elevation [5].”
BackgroundManagement of Acute Pancreatitis Associated With Checkpoint Inhibitors
Rogers, C. B. B., Cuddahy, T., & Zawislak, M. C. (2020) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2020.11.1.3 · Cited by 29
Manoria, P. C., Chopra, H. K., Parashar, S.-R., Dutta, A. L., Pinto, B., Mullasari, A., & Prajapati, S. (2013) · Indian Heart Journal · doi:10.1016/j.ihj.2013.10.015 · Cited by 32
Hypertriglyceridemia causes more severe course of acute pancreatitis
Baranyai, T., Terzin, V., Vajda, Á., Wittmann, T., & Czakó, L. (2012) · Clinical Lipidology · doi:10.2217/clp.12.69 · Cited by 31
Tamoxifen-induced hypertriglyceridemia causing acute pancreatitis
Singh, H. K., Prasad, M. S., Kandasamy, A., & Dharanipragada, K. (2016) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.179365 · Cited by 26
“The resultant release of pancreatic lipases causes release of free fatty acids from triglycerides followed by an inflammatory response.[5]”
BackgroundChylomicronemia Syndrome: Very Severe Hypertriglyceridemia and Acute Pancreatitis
Wierzbicki, A. S. (2018) · Endocrine and Metabolic Medical Emergencies · doi:10.1002/9781119374800.ch44 · Cited by 28
Dayspring, T. D. (2011) · International Journal of Women s Health · doi:10.2147/ijwh.s16702 · Cited by 28
“Hyperviscosity due to elevated serum FAs may also aggravate this condition.(38)”
Tai, W.-P., Lin, X.-C., Liu, H., Wang, C., Wu, J., Zhang, N., & Chen, W. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/6263095 · Cited by 25
Tan, H. L. E., McDonald, G., Payne, A. R., Yu, W., Ismadi, Z., Tran, H. A., Gani, J., & Wynne, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123954 · Cited by 25
“2 mmol/L (1000 mg/dL), though this number is somewhat arbitrary [11,12].”
BackgroundLi, P., Liu, X., Cui, B., Liu, Y., Wang, C., & Zhao, B. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.813083 · Cited by 23
“Severe hypertriglyceridemia, defined as a serum triglyceride level equal to or more than 1,000 mg/dL, is one of the most prevalent etiologies of acute pancreatitis (AP) (15, 16).”
Background
Metadata
- Authors
- Ewald, N., Hardt, P. D., & Kloer, H.-U.
- Affiliations
- Universitätsklinikum Gießen und Marburg (DE)
- Corresponding author
- Ewald, Nils
- Venue
- Current Opinion in Lipidology
- Published
- 2009-12
- Volume
- 20
- Issue
- 6
- Pages
- 497-504
- ISSN
- 0957-9672 (ISSN-L)
- OpenAlex
- W2009619895
- Cited by
- 273
- References
- 84
- Citations by year
- 2026: 12 · 2025: 7 · 2024: 16 · 2023: 17 · 2022: 11 · 2021: 16 · 2020: 22 · 2019: 17 · 2018: 15 · 2017: 9 · 2016: 23 · 2015: 17 · 2014: 20 · 2013: 24 · 2012: 15
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Lipidology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Gastroenterology › Gallbladder and Bile Duct Disorders
- Keywords
- hypertriglyceridemia-induced pancreatitis, severe hypertriglyceridemia, acute pancreatitis, lipoprotein metabolism disorders, pancreatic lipase, free fatty acids, apheresis, insulin therapy, heparin, lipid-lowering drugs, dietary change, chronic pancreatitis, pregnancy
- MeSH terms
- Fatty Acids, Humans, Hydrolysis, Lipase, Lipoproteins, Pancreatitis, Triglycerides, Hypertriglyceridemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.